Read the CJC-1295 + Ipamorelin Blend Research Guide. Review the research context and evidence limitations.
CJC-1295 (No DAC) + Ipamorelin Blend is supplied as one laboratory research vial in two options: CJC-1295 without DAC (Mod GRF 1-29) 5 mg + Ipamorelin 5 mg (10 mg total), or CJC-1295 without DAC 10 mg + Ipamorelin 10 mg (20 mg total), as selected. The CJC component is the supplier-confirmed no-DAC form, also named Mod GRF 1-29; no prolonged DAC half-life is claimed. The component amounts describe the listed material rather than a human dose or prepared solution concentration. The illustrated 3ml marking refers to container capacity.
Choose either 5mg/5mg (10mg total) or the existing 10mg/10mg (20mg total) option on this page. Both follow the same ingredient order, and the selected option controls the price and vial image. The larger option remains a separate inventory choice with its existing pricing and availability settings.
Preclinical ipamorelin work demonstrated GH release through a GHRP-like receptor. It did not test this packaged blend. The references below explain the specific study context. No direct study of this exact supplied blend was identified in this review. Comparisons should distinguish individual-component evidence from mixture-specific stability, interactions and biological activity; a source link is not an endorsement or batch certification.
Match the product designation, individual component identities and stated amounts against the relevant analytical report before drawing laboratory conclusions. The SRP research chart is explanatory, and the COA, chromatography, mass-spectrometry and traceability illustrations are educational examples, not test results for this vial. For laboratory research only; not for human or veterinary use, diagnosis or treatment.
Reviews
There are no reviews yet.